Denosumab, a human monoclonal antibody targeting receptor activator of nuclear factor κB ligand (RANKL), is widely used as an antiresorptive agent in the management of osteoporosis, treatment-induced bone loss, and cancer-related skeletal disease [2]. The gene discussed is TNFSF11; the disease is osteoporosis.